Der Nervenarzt

, Volume 74, Issue 8, pp 726–727 | Cite as

Statininduziertes Parkinson-Syndrom

Leserbrief zum Beitrag von J. Finsterer in "Der Nervenarzt" (2003) 74:115–122
Leserbrief
First Online:
This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Finsterer J (2003) Fibrat-/Statin-Myopathie. Nervenarzt 74:115–122Google Scholar
  2. 2.
    Müller T, Kuhn W, Pöhlau D, Przuntek H (1995) Parkinsonism unmasked by lovastatin. Ann Neurol 37:685–686Google Scholar
  3. 3.
    Simons M, Schwarzler F, Lutjohann D et al. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double- blind trial. Ann Neurol 52:346–350Google Scholar
  4. 4.
    Folkers K, Langsjoen P, Willis R et al. (1990) Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 87:8931–8934Google Scholar
  5. 5.
    Shults CW, Haas RH, Passov D, Beal MF (1997) Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42:261–264Google Scholar
  6. 6.
    Rotig A, Appelkvist EL, Geromel V et al. (2000) Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356:391–395Google Scholar
  7. 7.
    Schapira AH, Mann VM, Cooper JM, Krige D, Jenner PJ, Marsden CD (1992) Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 [Suppl]:116–124Google Scholar
  8. 8.
    Chan A, Reichmann H, Kogel A, Beck A, Gold R (1998) Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 245:681–685Google Scholar
  9. 9.
    Haas RH, Nasirian F, Nakano K et al. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37:714–722Google Scholar
  10. 10.
    Shults CW, Oakes D, Kieburtz K et al. (2002) Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550Google Scholar
  11. 11.
    Fuente-Fernandez R, Stoessl AJ (2002) The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof 25:387–398Google Scholar
  12. 12.
    Müller T, Buttner T, Gholipour A, Kuhn W (2003) Coenzyme Q10 supplementation mildly improves treated patients with Parkinson's disease. Neuroscience Letters 8; 341(3): 201–204Google Scholar
  13. 13.
    Feigin A, Kieburtz K, Como P et al. (1996) Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11:321–323Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Neurologische Universitätsklinik im St. Josef-HospitalRuhr-Universität BochumBochum
  2. 2.Neurologische Universitätsklinik im St. Josef-HospitalRuhr-Universität Bochum

Personalised recommendations